Lexostad

Bromazepam, the active ingredient in Lexostad, is a benzodiazepine presented as an oral tablet for oral administration. It acts as an anxiolytic, providing short‑term relief of anxiety symptoms and helping to manage generalized anxiety disorder and related conditions in adult patients.

GNH USA supplies Lexostad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. Our network facilitates reliable sourcing, batch traceability, and timely delivery to meet the needs of healthcare providers.

Bromazepam is a benzodiazepine anxiolytic that modulates the GABA‑A receptor pathway to reduce anxiety. - Anxiety disorders: reduction of excessive worry and tension in affected individuals. - Generalized anxiety disorder: alleviation of persistent, uncontrolled anxiety symptoms. - Short‑term relief of anxiety symptoms: rapid calming effect during acute stress episodes.

Bromazepam may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: light‑headed sensation, especially when standing quickly. - Impaired coordination: reduced motor control and clumsiness. - Memory impairment: difficulty recalling recent events. - Blurred vision: temporary visual disturbances. - Fatigue: persistent lack of energy.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Severe hypotension: marked drop in blood pressure leading to fainting. - Paradoxical reactions: increased anxiety, agitation, or aggression. - Dependence and withdrawal: risk of physical dependence with prolonged use. - Seizures: rare occurrence during abrupt discontinuation. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before prescribing Bromazepam, clinicians should evaluate patient-specific factors and monitor for potential risks. - Assess patient history: screen for depression, substance abuse, and respiratory disease. - Evaluate concomitant CNS depressants: avoid additive sedation. - Use caution in the elderly: increased sensitivity to sedative effects. - Monitor renal and hepatic function: adjust use if impairment is present. - Avoid abrupt discontinuation: taper dose under medical supervision. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Bromazepam can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Alcohol: synergistic CNS depression leading to profound sedation. - Opioids: combined respiratory depression and heightened sedation risk. - Other benzodiazepines: additive sedative effects and increased dependence potential.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs): may enhance CNS effects. - Antihistamines: can increase drowsiness. - CYP3A4 inhibitors (e.g., erythromycin): may raise bromazepam plasma levels. - Oral contraceptives: potential alteration of hormone metabolism.